成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 123318-82-1 Chemical Structure| 123318-82-1

Structure of Clofarabine
CAS No.: 123318-82-1

Chemical Structure| 123318-82-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 123318-82-1

,{[proInfo.pro_purity]}

Clofarabine inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase.

Synonyms: Clolar; Evoltra; C1-F-Ara-A

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Clofarabine

CAS No. :123318-82-1
Formula : C10H11ClFN5O3
M.W : 303.68
SMILES Code : NC1=C2N=CN([C@H]3[C@@H](F)[C@@H]([C@@H](CO)O3)O)C2=NC(Cl)=N1
Synonyms :
Clolar; Evoltra; C1-F-Ara-A
MDL No. :MFCD00871077
InChI Key :WDDPHFBMKLOVOX-AYQXTPAHSA-N
Pubchem ID :119182

Safety of Clofarabine

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H300
Precautionary Statements:P264-P301+P310
Class:6.1
UN#:2811
Packing Group:

Related Pathways of Clofarabine

DNA

Isoform Comparison

Biological Activity

Target
  • ribonucleotide reductase

    Ribonucleotide reductase, IC50:65 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
A375 30 nM 24 hours Induced G2/M phase cell cycle arrest PMC11804206
A549 1 μM 24 hours Induced G2/M phase cell cycle arrest PMC11804206
TC-71 10 μM 48 h To evaluate the cytotoxicity of Clofarabine on TC-71 cells, results showed that Clofarabine significantly inhibited cell proliferation. PMC9936921
RDES 10 μM 48 h To evaluate the cytotoxicity of Clofarabine on RDES cells, results showed that Clofarabine significantly inhibited cell proliferation. PMC9936921
B16F10 1.5 μM 48 hours Induced apoptosis PMC11804206
A4573 3 μM 6 h To evaluate the cytotoxicity of Clofarabine on A4573 cells, results showed that Clofarabine significantly inhibited cell proliferation. PMC9936921
K562 cells 8 nM 72 hours To evaluate the therapeutic effects of Clofarabine in combination with RSV or ATRA on CML cells, the results showed significant inhibition of cell growth and induction of caspase-3-dependent apoptosis. PMC6755200

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SCID/beige mice TC-71 xenograft model Oral 30 mg/kg Once daily for 14 days To evaluate the antitumor activity of Clofarabine in the TC-71 xenograft model, results showed that Clofarabine significantly inhibited tumor growth and prolonged event-free survival. PMC9936921

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02425904 Langerhans Cell Histiocytosis PHASE2 ACTIVE_NOT_RECRUITING 2025-01-25 Phoenix Children's Hospital, P... More >>hoenix, Arizona, 85016, United States|Arkansas Children's Hospital, Little Rock, Arkansas, 72202, United States|Children's Hospital of Los Angeles, Los Angeles, California, 90027, United States|University of California San Francisco Medical Center, San Francisco, California, 94143, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Boston Children's Hospital, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Mount Sinai Medical Center, New York, New York, 10029, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|The Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States|Texas Children's Hospital, Houston, Texas, 77030, United States|The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada Less <<
NCT00338494 B-Cell Lymphoma PHASE1 COMPLETED 2025-04-11 Yale Comprehensive Cancer Cent... More >>er at Yale University School of Medicine, New Haven, Connecticut, 06520, United States Less <<
NCT00727766 Leukemia, Myeloid, Acute PHASE1 COMPLETED 2025-11-14 Washington University, St. Lou... More >>is, Missouri, 63110, United States Less <<
NCT00299156 Myelodysplastic Syndrome|Chron... More >>ic Myelomonocytic Leukemia Less << PHASE2 COMPLETED 2025-12-12 U.T.M.D. Anderson Cancer Cente... More >>r, Houston, Texas, 77030, United States Less <<
NCT01796405 Langerhans Cell Histiocytosis PHASE2 WITHDRAWN - -
NCT01196013 Acute Lymphoblastic Leukemia PHASE1 COMPLETED 2025-05-11 National Kyusyu Cancer Center,... More >> Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Kagoshima University Medical and Dental Hospital, Kagoshima, Japan|Tokai University Hospital, Kanagawa, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka City General Hospital, Osaka, Japan|Saitama Chilidren's Medical Center, Saitama, Japan|Shizuoka Children's Hospital, Shizuoka, Japan|St. Luke's International Hospital, Tokyo, Japan Less <<
NCT00028418 Hematologic Neoplasms|Lymphopr... More >>oliferative Disorders|Leukemia|Leukemia, Lymphocytic, Chronic Less << PHASE1 COMPLETED 2025-03-04 University of Texas M. D. Ande... More >>rson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT01065545 Acute Myeloid Leukemia PHASE1 WITHDRAWN - -
NCT00081887 Chronic Lymphocytic Leukemia|L... More >>eukemia Less << PHASE1 TERMINATED 2025-06-07 The University of Texas M.D. A... More >>nderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT00201669 Non-Hodgkin's Lymphoma PHASE2 COMPLETED 2025-06-06 Ohio State University, Columbu... More >>s, Ohio, 43210, United States Less <<
NCT01169012 Myelodysplastic Syndrome|Acute... More >> Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Myelomonocytic Leukemia Less << PHASE1 COMPLETED 2025-01-13 University of North Carolina a... More >>t Chapel Hill, Chapel Hill, North Carolina, 27599, United States Less <<
NCT01063257 Myelodysplastic Syndrome PHASE1|PHASE2 COMPLETED 2025-03-14 H?pital Avicenne, Bobigny, 930... More >>09, France|Institut Paoli-Calmettes, Marseille, 13009, France|H?pital Saint-Louis, Paris, 75475, France|Hopital Cochin Service d'Hématologie, Paris, 75679, France|Centre Henri Becquerel, Rouen, 76038, France Less <<
NCT01279096 Acute Lymphoid Leukemia Relaps... More >>e|Acute Lymphoid Leukemia Relapse After Bone Marrow Transplant Less << PHASE1 COMPLETED 2025-06-13 Besan?on University Hospital, ... More >>Besan?on, 25000, France|Lille University Hospital, Lille, 59037, France Less <<
NCT00724009 Leukemia PHASE2 COMPLETED 2025-09-12 The University of Chicago hosp... More >>itals, Chicago, Illinois, 60637, United States Less <<
NCT00644189 Follicular Lymphoma|Marginal Z... More >>one Lymphoma|Mantle Cell Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma|Low Grade B-cell Lymphoma, Not Otherwise Specified|Diffuse Large B-cell Lymphoma|Peripheral T-cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large-cell Lymphoma Less << PHASE1|PHASE2 COMPLETED 2025-07-21 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States Less <<
NCT00422032 Myelodysplastic Syndrome|Leuke... More >>mia Less << PHASE2 COMPLETED 2025-11-11 UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less <<
NCT01188174 AML PHASE2 COMPLETED 2025-12-14 CHU de Bordeaux, Bordeaux, Fra... More >>nce|CHU Caen, Caen, France|CHRU lille, Lille, France|H?pital Edouard Herriot, Lyon, France|Institut Paoli Calmette, Marseille, France|Nantes University hospital, Nantes, 44200, France|Paris saint Louis, Paris, France|CHRU de Strasbourg, Strasbourg, France|CHU Toulouse, Toulouse, France Less <<
NCT00531232 Myelodysplastic Syndromes|Seco... More >>ndary Acute Myeloid Leukemia (AML) Less << PHASE2 COMPLETED 2011-05-12 The University of Chicago, Chi... More >>cago, Illinois, 60637, United States|Weill Medical College of Cornell University, New York, New York, 10065, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, 27157, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Baylor University Medical Center Blood Marrow Transplantation Research, Dallas, Texas, 75246, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT00241371 Multiple Myeloma PHASE2 TERMINATED 2025-12-07 Washington University School o... More >>f Medicine, St. Louis, Missouri, 63110, United States Less <<
NCT01295307 Acute Myeloid Leukemia PHASE2 COMPLETED 2025-12-13 HELIOS Klinikum Bad Saarow, Ba... More >>d Saarow, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|University Hospital Carl Gustav Carus, Dresden, 01307, Germany|Universit?tsklinikum Erlangen, Erlangen, Germany|Klinikum der J. W. Goethe-Universit?t, Frankfurt am Main, Germany|Klinikum Mannheim GmbH, Mannheim, Germany|Universit?tsklinikum Münster, Münster, Germany|Klinikum Nürnberg Nord, Nürnberg, Germany|Universit?tsklinikum Tübingen, Tübingen, Germany|Universit?tsklinikum Würzburg, Würzburg, Germany Less <<
NCT02544789 Acute Lymphoblastic Leukemia PHASE2 COMPLETED 2025-05-12 Department of Pediatrics, Peki... More >>ng University People's Hospital, Beijing, China|Department of Phase 1 Clinical Trial, Peking University People's Hospital, Beijing, China|Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, China|The First Hospital of China Medical University, Shenyang, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China Less <<
NCT00708721 Cancer|Chronic Myelomonocytic ... More >>Leukemia Less << PHASE1|PHASE2 TERMINATED 2025-11-14 Huntsman Cancer Institute, Sal... More >>t Lake City, Utah, 84112, United States Less <<
NCT01003678 Myelodysplastic Syndrome PHASE1 TERMINATED 2025-10-13 Roswell Park Cancer Institute,... More >> Buffalo, New York, 14263, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.29mL

0.66mL

0.33mL

16.46mL

3.29mL

1.65mL

32.93mL

6.59mL

3.29mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories